STOCKHOLM, SE / ACCESS Newswire / April 3, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that its Annual Report for 2024 has been published.
"2024 was yet another active and successful year for AlzeCure Pharma. The year began with new preclinical data in our clinical Alzheimer's program showing that NeuroRestore ACD856 has neuroprotective and disease-modifying effects. We have subsequently initiated preparatory work for Phase II clinical studies with the compound. In our second Alzheimer's project, Alzstatin, we decided to proceed with our latest molecule, ACD680, which is now being prepared for clinical trials. In the pain project targeting knee osteoarthritis, TrkA-NAM ACD137, we selected a candidate drug at the beginning of the year and presented preclinical data showing that ACD137 has at least as good analgesic effects as the antibody Tanezumab, and also potentially protective effects.
To finance the continued development of our drug candidates and strengthen the company's financial position, we conducted a new share issue during the year, which raised SEK 45 million (before expenses). The Board of Directors was also strengthened with Dr. Jan Lundberg, former Global Head of Research and Development at Eli Lilly.
In 2024, we applied for grants from the EU, and in early 2025, we achieved this milestone when we were awarded a grant of EUR 2.5 million under the Accelerator program, with the potential for additional financing through the EIC Fund. We are very proud and honored to receive this prestigious grant, which will accelerate our clinical development and bring us closer to the goal of delivering a transformative therapy for Alzheimer's patients ."
Martin Jönsson
CEO of AlzeCure Pharma
The Annual Report is attached as a PDF and is available on the company's website, https://www.alzecurepharma.se/en/section/investors/financial-reports/
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease and is being prepared for phase 2. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain with positive phase 2 results, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se.
Attachments
Alzecure AR 2024 ENG
SOURCE: AlzeCure Pharma
View the original press release on ACCESS Newswire
